Cargando…

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

PURPOSE: Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., Michalopoulou, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180559/ https://www.ncbi.nlm.nih.gov/pubmed/21301848 http://dx.doi.org/10.1007/s00280-011-1572-5

Ejemplares similares

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005)

Combination of three cytotoxic agents in small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2012)

Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008)

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
por: White, S C, et al.
Publicado: (2006)

Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer
por: Sun, Mengwei, et al.
Publicado: (2019)

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
por: Chen, Yi, et al.
Publicado: (2017)

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
por: Belani, Chandra P, et al.
Publicado: (2014)

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
por: Rose, Maimon C., et al.
Publicado: (2014)

Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities
por: Riaz, Muhammad Assad, et al.
Publicado: (2019)

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol
por: Kreuter, Michael, et al.
Publicado: (2007)

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
por: Gao, Jing, et al.
Publicado: (2016)

Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2021)

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer
por: Zhao, Chenchen, et al.
Publicado: (2021)

Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
por: Xu, Bei, et al.
Publicado: (2018)

Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
por: Watanabe, Kana, et al.
Publicado: (2021)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2020)

MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
por: Fadejeva, Irina, et al.
Publicado: (2017)

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
por: Han, Ji-Youn, et al.
Publicado: (2017)

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
por: Woods, R. L., et al.
Publicado: (1990)

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G(2)/M cell cycle arrest
por: Sarin, Navin, et al.
Publicado: (2017)

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
por: Yang, C H, et al.
Publicado: (2002)

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
por: Azar, Ibrahim, et al.
Publicado: (2022)

Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway
por: Chen, Yun, et al.
Publicado: (2020)

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
por: Earle, C C, et al.
Publicado: (1999)

SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer
por: SHEN, LIHUA, et al.
Publicado: (2016)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
por: Xiao, Lu, et al.
Publicado: (2017)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial
por: Yao, Lei, et al.
Publicado: (2015)

Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
por: Paul, I, et al.
Publicado: (2012)

Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study
por: Kamath, Mangesh P, et al.
Publicado: (2016)

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells()()
por: Bar, Jair, et al.
Publicado: (2016)

Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2
por: Misri, Swati, et al.
Publicado: (2022)

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
por: Ellis, P. A., et al.
Publicado: (1995)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells
por: Wang, Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h8odvqec260l8m10muo3d8m526